The most recent Form 13F filing that DekaBank Deutsche Girozentrale submitted to the Securities and Exchange Commission reveals that during the third quarter of 2018, the financial institution increased the number of shares of Novanta Inc. (NASDAQ: NOVT) that it owned by 1.6%. The institutional investor now has 160,000 shares of the stock after purchasing an additional 2,500 shares of the technology company’s stock during the quarter. The investor’s holdings in the stock have increased by $2,500. After the most recent financial quarter, DekaBank Deutsche Girozentrale held approximately 0.45% of Novanta, valued at $18,799,000.
Hedge funds and other types of institutional investors have been increasing the percentage of their holdings invested in the company over the past few months. During the second quarter, Heritage Wealth Management LLC increased its ownership stake in Novanta by investing approximately $28,000. Around $32,000 was put up by GHP Investment Advisors Inc. during the third quarter as an investment in Novanta so that they could obtain a larger share of the company. The percentage of Novanta shares that Lazard Asset Management LLC owned grew by 23.1% during the first three months of the year, thanks to the company’s expansion. After purchasing an additional 183 shares during the most recent quarter, Lazard Asset Management LLC now owns a total of 976 shares of the technology company’s stock, which has a value of $138,000 after accounting for the most recent quarter’s acquisitions (down from 1,076 shares before). During the first three months of 2018, the value of the portfolio of Novanta shares held by Captrust Financial Advisors skyrocketed upward by 227.3%. Captrust Financial Advisors now has 1,545 shares of the technology company’s stock after purchasing an additional 1,073 shares during the most recent quarter. The stock is valued at $220,000 because Captrust Financial Advisors owns all the shares. Quantbot Technologies LP made one last investment during the second quarter, purchasing a new position in Novanta stock with a value of approximately $192,000. This is by no means the least important of the three. The company’s stock is held collectively by hedge funds and other institutional investors to 97.55 percent of the total.
The opening price of the New York Stock Exchange (NOVT) stock market was $151.95 per share on Thursday. The ratio of current assets to total assets is 2.58, the ratio of quick assets to current assets is 1.55, and the ratio of total assets to current assets is 0.81. The moving average of the company’s stock price over the previous 200 days is $138.62, and the moving average over the previous 50 days is $147.85. Both the price-to-earnings ratio for the company’s stock, which is 74.85, and the stock’s beta value, which is 1.30, are extremely high. The total value of the company on the market is calculated to be $5.42 billion. In the past year, Novanta Inc.’s stock price ranged from a low of $110.84 to a high of $162.48. The average price during that period was $162.48.
November 8, Novanta (NASDAQ: NOVT) released its most recent quarterly earnings report. The technology company announced earnings of $0.81 per share for the quarter, which is $0.08 more than the consensus estimate of $0.73 per share among market experts. Novanta had a return on equity of 20.16 percent, and the net margin for the company was 8.62 percent. The revenue the company brought in for the quarter was $222.96 million, which is significantly higher than the $215.01 million in revenue projected for the company throughout the quarter. Sell-side analysts forecast that Novanta Inc. will bring in $3.01 in earnings per share for the current fiscal year.
In other Novanta news, director Thomas N. Secor sold 550 shares of the company’s stock on Monday, October 24. This transaction took place earlier this week. Earlier this week, this transaction was carried out. There were 6,8750 transactions involving the company’s stock, with each share selling for an average of $125.00. Because of the transaction, the director now has direct ownership of 1,655 company shares, and the total value of those shares is $206,875. If you follow this link, you will be taken to the filing submitted to the Securities and Exchange Commission, where the transaction was discussed, and it will take you there immediately. In other news about this topic, on October 24, company director Thomas N. Secor sold 550 of the company’s shares of stock. There were 6,8750 transactions involving the company’s stock, with each share selling for an average of $125.00. The director now has a total of 1,655 shares of the company, which have a value of $206,875; the paperwork that describes the transaction was sent to the Securities and Exchange Commission, which can be found on the website of the SEC. The transaction resulted in the director having a total of 1,655 shares. In addition, on November 15, 20,000 of the company’s shares of equity were sold by Matthijs Glastra, the company’s CEO. It was determined that the average selling price for the stock was $160.06 per share, and a total of $3,201,200.00 worth of the stock was transacted. As soon as the deal is finalized, the company’s CEO will become the owner of 86,558 shares. Based on the current market price, these shares are worth approximately $13,854,473.48. Disclosures that are related to the sale might be found in this section of the website. According to the most recent available data, insiders of the company have sold 47,044 shares of company stock over the past three months for a total price of $7,150,713. 1.40 company insiders own a percent of the total shares currently outstanding.
In a separate development, a research report on Novanta shares was released by StockNews.com on October 12the same day that the website began reporting on the company’s stock. They advised their clients to purchase the stock.
The products that Novanta Inc. and its subsidiaries are designing, producing, marketing, and distributing to original equipment manufacturers working in the medical and industrial sectors around the world are components and subsystems for photonics, vision, and precision motion. The Photonics division of the company offers photonics-based solutions for a wide range of applications, such as medical and life science imaging, industrial processing, metrology, DNA sequencing, and medical laser treatments, among others. Products such as CO2 lasers, solid-state lasers, ultrafast lasers, and optical light engines are examples of those that are included in this category of items.